1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Rising prevalence of non-Hodgkin lymphoma disease
5.2.2. High unmet clinical needs and the launch of promising drugs
5.2.3. NHL patient prognosis and standard of care in front-line treatment regimens
5.3. Restraints
5.3.1. High cost of the treatment and certain side effects
5.4. Opportunities
5.4.1. Increase in research and development of therapeutic drugs against the disease
5.4.2. Rising investments from government and non-profit organizations
5.5. Challenges
5.5.1. Lack of awareness and limited resources

6. Non-Hodgkin Lymphoma Treatment Market, by Treatment
6.1. Introduction
6.2. Chemotherapy
6.3. Immunotherapy
6.4. Radiation
6.5. Stem Cell Transplant
6.6. Targeted Therapy

7. Non-Hodgkin Lymphoma Treatment Market, by Cell Type
7.1. Introduction
7.2. B-cell
7.3. T-cell

8. Americas Non-Hodgkin Lymphoma Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand

10. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. AbbVie Inc.
12.2. Amgen, Inc.
12.3. AstraZeneca PLC
12.4. Bayer AG
12.5. Bristol Myers Squibb Company
12.6. Eli Lilly and Company
12.7. F. Hoffmann-La Roche Ltd
12.8. GlaxoSmithKline PLC
12.9. Kyowa Kirin Co., Ltd.
12.10. Merck KGaA
12.11. Nordic Nanovector ASA
12.12. Novartis AG
12.13. Pfizer Inc.
12.14. Pharmacyclics, LLC
12.15. Sanofi SA

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: MARKET DYNAMICS
FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2020 VS 2026 (%)
FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2020 VS 2026 (USD MILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2026
FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2026 (USD MILLION)
FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2026 (USD MILLION)
FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, 2018-2026 (USD MILLION)
FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, 2018-2026 (USD MILLION)
FIGURE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2026 (USD MILLION)
FIGURE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2020 VS 2026 (%)
FIGURE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2020 VS 2026 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2026
FIGURE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, 2018-2026 (USD MILLION)
FIGURE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, 2018-2026 (USD MILLION)
FIGURE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, BY REGION, 2020 VS 2026 (USD MILLION)
FIGURE 24. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 25. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 26. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 27. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 28. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 29. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 30. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 31. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 32. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 33. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 34. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 35. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 36. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 37. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 38. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 39. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 40. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 41. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 42. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 43. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 44. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 45. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 46. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 47. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 48. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 49. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 50. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 51. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 52. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 53. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 54. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: FPNV POSITIONING MATRIX
FIGURE 55. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 56. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION, BY REGION, 2018-2026 (USD MILLION)
TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2026 (USD MILLION)
TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2026 (USD MILLION)
TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2026 (USD MILLION)
TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL, BY REGION, 2018-2026 (USD MILLION)
TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL, BY REGION, 2018-2026 (USD MILLION)
TABLE 13. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 14. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 15. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 16. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 17. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 18. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 19. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 20. AUSTRALIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 21. CHINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 22. INDIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 23. INDONESIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 24. JAPAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 25. MALAYSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 26. PHILIPPINES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 27. SINGAPORE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 28. SOUTH KOREA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 29. TAIWAN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 30. THAILAND NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 31. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 32. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 33. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 34. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 35. NETHERLANDS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 36. QATAR NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 37. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 38. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 39. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 40. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 41. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 42. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 43. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: SCORES
TABLE 44. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: BUSINESS STRATEGY
TABLE 45. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: PRODUCT SATISFACTION
TABLE 46. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: RANKING
TABLE 47. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 48. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: MERGER & ACQUISITION
TABLE 49. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 50. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 51. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: INVESTMENT & FUNDING
TABLE 52. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 53. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET: LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
Amgen, Inc.
AstraZeneca PLC
Bayer AG
Bristol Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Kyowa Kirin Co., Ltd.
Merck KGaA
Nordic Nanovector ASA
Novartis AG
Pfizer Inc.
Pharmacyclics, LLC
Sanofi SA